SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Inclusion Criteria: * Age ≥ 12 years of age * Patients with unresectable or metastatic histologically confirmed sporadic or NF1 associated MPNST. * Patients must have measureable disease by RECIST. * Patients must have experienced progression after one or more prior regimens of cytotoxic chemotherapy. Patients who have refused cytotoxic chemotherapy or for whom treatment on this protocol prior to receiving cytotoxic chemotherapy is felt to be in the best interest for the patient by the local investigator will also be eligible. * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study. * No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry. * The last dose of all myelosuppressive anticancer drugs must be at least 3 weeks prior to study entry. * The last dose of immunotherapy (monoclonal antibody or vaccine) must be at least 4 weeks prior to study entry. * The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry. * The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry. The last dose of all other local palliative (limited port) radiation must be at least 2 weeks prior to study entry. * At least 2 months post-autologous st…